Business Trends– category –
-
CAR-T Cell Therapy for Autoimmune Diseases Achieves 40-60% Cost Reduction and Sub-7-Day Manufacturing Through Gene Editing and Process Optimization
Market Intelo USA Overview Advances in gene-editing technologies are significantly reducing alloreactivity risk in allogeneic CAR-T products and cutting production costs by an estimated 40-60%. Next-generation allogeneic platforms aim to... -
Syntax Bio and Applied StemCell Partner to Accelerate Allogeneic Cell Therapies with GMP-Compliant Hypoimmune iPSCs and Cellgorithm Platform
CRISPR Medicine News USA Overview Syntax Bio and Applied StemCell have forged a strategic collaboration to propel next-generation regenerative medicine by advancing stem cell innovation. Applied StemCell will supply GMP-compatible hypoim... -
Bioprocessing Technologies Reshape Food Production, Environmental Applications, and Sustainable Manufacturing Beyond Pharma
Technology Networks Global Overview Bioprocessing technologies are redefining various industries beyond pharmaceuticals, including food production, environmental applications, and sustainable manufacturing. Key technologies like fermenta... -
REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stemchymal® Stem Cell Therapy for Spinocerebellar Ataxia (SCA3 and SCA6)
BioSpace Japan Overview REPROCELL Inc. has submitted an application for manufacturing and marketing approval in Japan for its regenerative medicine product, Stemchymal®, aimed at inhibiting the progression of motor ataxia in patients wit... -
UniXell Biotechnology Secures US FDA IND Clearance for Off-the-Shelf Parkinson’s Cell Therapy UX-DA003, Accelerating Dual China-US Clinical Development
BioPharma APAC USA Overview UniXell Biotechnology announced that its allogeneic iPSC-derived therapy UX-DA003 for Parkinson's disease has received Investigational New Drug (IND) approval from the US FDA. This approval enables the company... -
Syntax Bio & Applied StemCell Partner to Accelerate Allogeneic iPSC Therapies with Low-Immunogenicity Lines and Cellgorithm Platform
Manufacturing Chemist USA Overview Syntax Bio and Applied StemCell have formed a strategic partnership to accelerate programmable iPSC therapy development. This collaboration aims to address key challenges of immune recognition and manuf... -
Japan Leads Global Ophthalmic Regenerative Medicine with First iPSC Retinal Transplant and Cultured Corneas, Backed by Proactive Regulation
Ophthoagent Japan Overview Japan has cemented its global leadership in advanced ophthalmic regenerative medicine, achieving groundbreaking clinical successes such as the world's first iPSC-derived retinal transplant in 2014 and successfu... -
Thermo Fisher Scientific Unveils DynaXS Single-Use Bioreactor and Global Manufacturing Expansion at BIO 2026, Boosting Cell & Gene Therapy Production
Business Wire USA Overview Thermo Fisher Scientific announced significant new manufacturing capabilities and AI-enabled research advancements at BIO International 2026, aiming to strengthen the cell and gene therapy sector. Key highlight... -
SK pharmteco Unveils SKyvec™ Viral Vector Platform, Boosting AAV Productivity by 5-6 Fold for Gene Therapy Development
Contract Pharma Global Overview SK pharmteco has launched its innovative 'SKyvec™ Viral Vector Platform,' designed to accelerate gene therapy development. This platform supports adeno-associated virus (AAV), lentivirus, and adenovirus ve... -
iPSC-Derived Immune Cells Pave Way for Scalable Allogeneic T-Cell Therapy Platforms in Cancer Immunotherapy
MDPI Global Overview Allogeneic T-cell therapies are rapidly advancing as a promising strategy in cancer immunotherapy to overcome the logistical and manufacturing challenges inherent in autologous approaches. Crucially, induced pluripot...
